- Home
- DTI vs ALXO Comparison
DTI vs ALXO Comparison
Compare DTI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTI
- ALXO
- Stock Information
- Founded
- DTI 1984
- ALXO 2015
- Country
- DTI United States
- ALXO United States
- Employees
- DTI 447
- ALXO N/A
- Industry
- DTI Metal Fabrications
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- DTI Industrials
- ALXO Health Care
- Exchange
- DTI Nasdaq
- ALXO Nasdaq
- Market Cap
- DTI 68.0M
- ALXO 76.5M
- IPO Year
- DTI N/A
- ALXO 2020
- Fundamental
- Price
- DTI $1.88
- ALXO $0.55
- Analyst Decision
- DTI Strong Buy
- ALXO Strong Buy
- Analyst Count
- DTI 1
- ALXO 6
- Target Price
- DTI $5.50
- ALXO $4.14
- AVG Volume (30 Days)
- DTI 114.2K
- ALXO 529.8K
- Earning Date
- DTI 05-08-2025
- ALXO 05-08-2025
- Dividend Yield
- DTI N/A
- ALXO N/A
- EPS Growth
- DTI N/A
- ALXO N/A
- EPS
- DTI 0.09
- ALXO N/A
- Revenue
- DTI $154,446,000.00
- ALXO N/A
- Revenue This Year
- DTI $12.21
- ALXO N/A
- Revenue Next Year
- DTI $6.26
- ALXO N/A
- P/E Ratio
- DTI $20.89
- ALXO N/A
- Revenue Growth
- DTI 1.59
- ALXO N/A
- 52 Week Low
- DTI $1.43
- ALXO $0.46
- 52 Week High
- DTI $6.36
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- DTI 38.67
- ALXO 37.26
- Support Level
- DTI $1.75
- ALXO $0.46
- Resistance Level
- DTI $2.03
- ALXO $0.63
- Average True Range (ATR)
- DTI 0.29
- ALXO 0.06
- MACD
- DTI 0.00
- ALXO 0.02
- Stochastic Oscillator
- DTI 38.14
- ALXO 42.86
About DTI Drilling Tools International Corporation
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.